Published in Hepatology on August 01, 2007
Cellular and molecular mechanisms of fibrosis. J Pathol (2008) 14.01
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol (2010) 3.30
Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet (2009) 3.24
Evolving therapies for liver fibrosis. J Clin Invest (2013) 2.59
Toll-like receptors as targets in chronic liver diseases. Gut (2009) 2.29
Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology (2010) 2.23
Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol (2011) 1.79
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology (2009) 1.72
Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology (2015) 1.68
Hepatic fibrosis. Curr Opin Gastroenterol (2009) 1.67
Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol (2011) 1.55
A large-scale rheumatoid arthritis genetic study identifies association at chromosome 9q33.2. PLoS Genet (2008) 1.53
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47
Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34
Toll-like receptors, wound healing, and carcinogenesis. J Mol Med (Berl) (2008) 1.27
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract (2010) 1.20
Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res (2014) 1.17
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des (2013) 1.16
Mononuclear cells in liver fibrosis. Semin Immunopathol (2009) 1.15
Toll-like receptor 4 and hepatic fibrogenesis. Semin Liver Dis (2010) 1.13
The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int (2010) 1.12
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology (2012) 1.09
Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair (2010) 1.09
Gene expression and hepatitis C virus infection. Gut (2008) 1.08
The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol (2012) 1.07
Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med (2007) 1.07
Liver fibrosis: mechanisms of immune-mediated liver injury. Cell Mol Immunol (2011) 1.06
From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer (2013) 1.05
Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci (2015) 1.05
Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms. Front Physiol (2012) 1.05
Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J (2014) 1.05
Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol (2009) 1.02
Immune dysfunction in cirrhosis. World J Gastroenterol (2014) 1.02
Regulation of wound healing and organ fibrosis by toll-like receptors. Biochim Biophys Acta (2012) 0.99
Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol (2010) 0.99
Liver biopsy in modern clinical practice: a pediatric point-of-view. Adv Anat Pathol (2012) 0.98
Aquaporin-1 facilitates angiogenic invasion in the pathological neovasculature that accompanies cirrhosis. Hepatology (2010) 0.98
Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol (2014) 0.97
Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol (2014) 0.97
Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. World J Hepatol (2012) 0.95
Hepatitis C virus infection is blocked by HMGB1 released from virus-infected cells. J Virol (2011) 0.95
Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci (2014) 0.95
A DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cells. J Biol Chem (2009) 0.93
The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol (2012) 0.91
A frequent variant in the human bile salt export pump gene ABCB11 is associated with hepatitis C virus infection, but not liver stiffness in a German population. BMC Gastroenterol (2012) 0.90
Genomics and proteomics in liver fibrosis and cirrhosis. Fibrogenesis Tissue Repair (2012) 0.90
Toll-like receptor 4 gene (TLR4), but not TLR2, polymorphisms modify the risk of tonsillar disease due to Streptococcus pyogenes and Haemophilus influenzae. Clin Vaccine Immunol (2010) 0.89
Toll-like receptor deficiency worsens inflammation and lymphedema after lymphatic injury. Am J Physiol Cell Physiol (2011) 0.89
Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol (2015) 0.88
Role of host genetics in fibrosis. Fibrogenesis Tissue Repair (2009) 0.86
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J (2011) 0.85
Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis. World J Gastrointest Pathophysiol (2010) 0.82
Host genetic variants in the pathogenesis of hepatitis C. Viruses (2012) 0.82
A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis. Hepatology (2011) 0.82
Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients. PLoS One (2015) 0.81
Host genetics predict clinical deterioration in HCV-related cirrhosis. PLoS One (2014) 0.81
The enteric microbiome in hepatobiliary health and disease. Liver Int (2015) 0.80
Alcohol and the Intestine. Biomolecules (2015) 0.80
Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics (2011) 0.80
Cytokine production in patients with cirrhosis and TLR4 polymorphisms. World J Gastroenterol (2014) 0.80
Evidence for a dominant major gene conferring predisposition to hepatitis C virus infection in endemic conditions. Hum Genet (2009) 0.79
Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases (2015) 0.79
YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int (2011) 0.79
The association of toll-like receptor 4 polymorphism with hepatitis C virus infection in Saudi Arabian patients. Biomed Res Int (2014) 0.78
Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray. J Transl Med (2012) 0.78
Functional characterization of breast cancer using pathway profiles. BMC Med Genomics (2014) 0.78
Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C. Transplantation (2014) 0.78
Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar? Curr Drug Targets (2015) 0.77
Age and ethnicity in cirrhosis. J Investig Med (2014) 0.77
Molecular prognostic prediction in liver cirrhosis. World J Gastroenterol (2015) 0.77
Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central Obesity. PLoS One (2016) 0.76
DNA methylation profiling identifies novel markers of progression in hepatitis B-related chronic liver disease. Clin Epigenetics (2016) 0.76
Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology (2016) 0.76
Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. World J Gastroenterol (2016) 0.76
Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C. J Clin Transl Hepatol (2014) 0.76
Systems genetics of hepatocellular damage in vivo and in vitro: identification of a critical network on chromosome 11 in mouse. Physiol Genomics (2013) 0.75
Toll-like receptors in secondary obstructive cholangiopathy. Gastroenterol Res Pract (2011) 0.75
Endotoxin receptor CD14 gene variants and histological features in chronic HCV infection. World J Gastroenterol (2009) 0.75
Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol (2017) 0.75
The great escape: microbiotal LPS takes a toll on the liver. Cancer Prev Res (Phila) (2012) 0.75
Transforming growth factor-β and toll-like receptor-4 polymorphisms are not associated with fibrosis in haemochromatosis. World J Gastroenterol (2013) 0.75
Identifying common genes and networks in multi-organ fibrosis. AMIA Jt Summits Transl Sci Proc (2012) 0.75
Starring role of toll-like receptor-4 activation in the gut-liver axis. World J Gastrointest Pathophysiol (2015) 0.75
Crosstalk Between Transforming Growth Factor Beta-2 and Toll-Like Receptor 4 in the Trabecular Meshwork. Invest Ophthalmol Vis Sci (2017) 0.75
Telomere shortening as genetic risk factor of liver cirrhosis. World J Gastroenterol (2015) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet (2001) 22.07
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet (2004) 13.71
A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet (2004) 10.87
Natural selection on protein-coding genes in the human genome. Nature (2005) 10.84
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet (2006) 9.56
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Inferring nonneutral evolution from human-chimp-mouse orthologous gene trios. Science (2003) 9.20
Assessing the evolutionary impact of amino acid mutations in the human genome. PLoS Genet (2008) 8.92
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet (2008) 7.07
Proportionally more deleterious genetic variation in European than in African populations. Nature (2008) 6.61
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
A physical map of the mouse genome. Nature (2002) 4.97
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Femtosecond protein nanocrystallography-data analysis methods. Opt Express (2010) 4.64
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am J Hum Genet (2005) 3.95
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol (2011) 3.66
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol (2011) 3.49
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology (2002) 2.85
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2004) 2.84
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A (2013) 2.79
Effects of a computerized system to support shared decision making in symptom management of cancer patients: preliminary results. J Am Med Inform Assoc (2003) 2.78
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature (2004) 2.74
Gene variants associated with deep vein thrombosis. JAMA (2008) 2.74
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology (2010) 2.68
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Acute aortic dissection: population-based incidence compared with degenerative aortic aneurysm rupture. Mayo Clin Proc (2004) 2.55
Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology (2003) 2.50
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol (2007) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
A survey of liver transplantation from living adult donors in the United States. N Engl J Med (2003) 2.37
Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol (2007) 2.36
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol (2010) 2.35
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol (2008) 2.21
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology (2010) 2.20
The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol (2012) 2.20
Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS (2004) 2.14
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol (2008) 2.12
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology (2006) 2.03
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology (2010) 2.02
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology (2009) 2.02
KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. Eur J Cardiovasc Prev Rehabil (2010) 1.98
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology (2006) 1.98
Evolutionary processes acting on candidate cis-regulatory regions in humans inferred from patterns of polymorphism and divergence. PLoS Genet (2009) 1.97
Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96
The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol (2011) 1.93
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med (2007) 1.92
Surgical treatment of non-small cell lung cancer 1 cm or less in diameter. Ann Thorac Surg (2002) 1.89
Identification of four gene variants associated with myocardial infarction. Am J Hum Genet (2005) 1.89
Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology (2002) 1.88
Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology (2003) 1.86
NAADP as a second messenger: neither CD38 nor base-exchange reaction are necessary for in vivo generation of NAADP in myometrial cells. Am J Physiol Cell Physiol (2006) 1.82
The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study. Am J Clin Pathol (2012) 1.79
Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol (2010) 1.78
Effect of hyponatraemia on outcomes following orthotopic liver transplantation. Liver Int (2009) 1.76
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology (2012) 1.76
ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. Circulation (2004) 1.76